BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25925586)

  • 1. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
    Hu C; Deng C; Zou W; Zhang G; Wang J
    Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
    Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
    Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
    Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
    Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.
    Lamy T; Damaj G; Soubeyran P; Gyan E; Cartron G; Bouabdallah K; Gressin R; Cornillon J; Banos A; Le Du K; Benchalal M; Moles MP; Le Gouill S; Fleury J; Godmer P; Maisonneuve H; Deconinck E; Houot R; Laribi K; Marolleau JP; Tournilhac O; Branger B; Devillers A; Vuillez JP; Fest T; Colombat P; Costes V; Szablewski V; Béné MC; Delwail V;
    Blood; 2018 Jan; 131(2):174-181. PubMed ID: 29061568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
    Dabaja BS; Vanderplas AM; Crosby-Thompson AL; Abel GA; Czuczman MS; Friedberg JW; Gordon LI; Kaminski M; Niland J; Millenson M; Nademanee AP; Zelenetz A; LaCasce AS; Rodriguez MA
    Cancer; 2015 Apr; 121(7):1032-9. PubMed ID: 25492236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.
    Marcheselli L; Marcheselli R; Bari A; Liardo EV; Morabito F; Baldini L; Brugiatelli M; Merli F; Di Renzo N; Sacchi S
    Leuk Lymphoma; 2011 Oct; 52(10):1867-72. PubMed ID: 21663499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
    Cassidy RJ; Jegadeesh N; Switchenko J; Danish H; Esiashvili N; Flowers CR; Khan MK
    Leuk Lymphoma; 2016 Aug; 57(8):1876-82. PubMed ID: 26759182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.
    Rozental A; Gafter-Gvili A; Vidal L; Raanani P; Gurion R
    Hematol Oncol; 2019 Feb; 37(1):27-34. PubMed ID: 30216478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
    Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
    Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
    Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
    J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.